[HTML][HTML] Omicron (B. 1.1. 529) variant of SARS‐CoV‐2: concerns, challenges, and recent updates
Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection
J Pušnik, WO Monzon-Posadas, J Zorn… - Nature …, 2023 - nature.com
The elicited anti-SARS-CoV-2 immunity is becoming increasingly complex with individuals
receiving a different number of vaccine doses paired with or without recovery from …
receiving a different number of vaccine doses paired with or without recovery from …
Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID‐19 cases: a challenging global threat with a special focus on …
The emergence of Omicron (B. 1.1. 529) variant of SARS‐CoV‐2 has resulted into a very
massive surge in COVID‐19 cases worldwide. Due to continuous emergence of multiple …
massive surge in COVID‐19 cases worldwide. Due to continuous emergence of multiple …
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
F Dotiwala, AK Upadhyay - Frontiers in Immunology, 2022 - frontiersin.org
The world has responded to the COVID-19 pandemic with unprecedented speed and vigor
in the mass vaccination campaigns, targeted to reduce COVID-19 severity and mortality …
in the mass vaccination campaigns, targeted to reduce COVID-19 severity and mortality …
Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants
Emerging SARS-CoV-2 variants of concern (VOCs) harboring multiple mutations in the spike
protein raise concerns on effectiveness of current vaccines that rely on the ancestral spike …
protein raise concerns on effectiveness of current vaccines that rely on the ancestral spike …
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus
Background People with human immunodeficiency virus (HIV) on antiretroviral therapy
(ART) with good CD4 T-cell counts make effective immune responses following vaccination …
(ART) with good CD4 T-cell counts make effective immune responses following vaccination …
Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study
Background The drive to vaccinate large populations is nowadays the main instrument for
combating the pandemic and preventing serious disease and death. However, breakthrough …
combating the pandemic and preventing serious disease and death. However, breakthrough …
[HTML][HTML] The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
C Saggau, GR Martini, E Rosati, S Meise, B Messner… - Immunity, 2022 - cell.com
SARS-CoV-2 infection and vaccination generates enormous host-response heterogeneity
and an age-dependent loss of immune-response quality. How the pre-exposure T cell …
and an age-dependent loss of immune-response quality. How the pre-exposure T cell …
A lyophilized colorimetric RT-LAMP test kit for rapid, low-cost, at-home molecular testing of SARS-CoV-2 and other pathogens
X Song, FJ Coulter, M Yang, JL Smith, FG Tafesse… - Scientific Reports, 2022 - nature.com
Access to fast and reliable nucleic acid testing continues to play a key role in controlling the
COVID-19 pandemic, especially in the context of increased vaccine break-through risks due …
COVID-19 pandemic, especially in the context of increased vaccine break-through risks due …
Cost-effectiveness analysis of molnupiravir versus best supportive care for the treatment of outpatient COVID-19 in adults in the US
H Goswami, A Alsumali, Y Jiang, M Schindler… - …, 2022 - Springer
Background and aims Coronavirus disease 2019 (COVID-19) imposes a substantial and
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …